Drug Trial Radar · NCT05127525
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Nov 15, 2021
Primary completion
Jan 31, 2022
Study completion Jan 31, 2022
Sponsor
- Lead sponsor
- iRenix Medical, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 30 centers in the United States (US).
Conditions
- Diabetic Macular Edema
- Branch Retinal Vein Occlusion
- Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101Drug
IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
ControlDrug
Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of infectious endophthalmitis after topical use of IRX-101 combined with IVTTime frame: 2 hours post-injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Florida
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.